The new era of biotech insulin analogues.
Many of the structural properties of insulin have evolved in response to the requirements of biosynthesis, processing, transport and storage in the pancreatic beta cells, properties that are not necessary for the biological action of the hormone. It is therefore not surprising that wild-type insulin has far from optimal characteristics for replacement therapy. For example, native human insulin self-associates to hexameric units, which limits the possibilities for the absorption of the molecule by various routes. During the last decade new techniques of molecular design have emerged and recombinant DNA technology offers new and exciting opportunities for rational protein drug design. This review describes examples of recent advances in insulin engineering aimed at optimizing the hormone for therapy. Such approaches focus on improvements in the pharmacokinetic properties, storage stability, and feasibility for less intrusive routes of administration.
Brange
J
J
Novo Nordisk A/S, Bagsvaerd, Denmark.
D000818:Animals; D001709:Biotechnology; D015195:Drug Design; D004355:Drug Stability; D005818:Genetic Engineering / Q000379:methods*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D007478:Iontophoresis; D008956:Models, Chemical; D015202:Protein Engineering / Q000379:methods*
D007328:Insulin